Skip to navigation Skip to content

COVID-19 Prophylactics & Therapeutics


Monoclonal antibody treatment: information for MS healthcare providers

*COVID-19 vaccines remain the best defense against infection and should continue to be prioritized.
This information is meant to facilitate shared decision-making conversations with your patients in the outpatient setting and to supplement our content on Suspected COVID-19 and MS and COVID-19 Vaccine Guidance for People Living with MS.
Some MS disease modifying therapies may reduce COVID-19 vaccine efficacy. Monoclonal antibody treatment for pre-exposure prophylaxis has been authorized for those who are not expected to have adequate immune responses to the vaccine or who have a severe allergy to the vaccine. Monoclonal antibody treatment for post-exposure prophylaxis and mild or moderate COVID-19 disease is also available for some people. View the full National Institutes of Health - Therapeutic Mangement of Nonhospitalized Adults with COVID-19.

Additional resources


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.